Antibody biomarkers in CNS demyelinating diseases - a long and winding road (Q28262403)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

review article

1 reference

title

Antibody biomarkers in CNS demyelinating diseases - a long and winding road (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

T Berger

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

English

0 references

publication date

24 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Neurology

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

1162-1168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods.

15 February 2020

cites work

1 reference

Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force

21 January 2018

1 reference

EFNS guidelines on disease-specific CSF investigations

21 January 2018

1 reference

B cells and antibodies in multiple sclerosis pathogenesis and therapy

21 January 2018

1 reference

Antibodies as biological markers for pathophysiological processes in MS.

21 January 2018

1 reference

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

21 January 2018

1 reference

Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.

21 January 2018

1 reference

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

21 January 2018

1 reference

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

EFNS guidelines on diagnosis and management of neuromyelitis optica

21 January 2018

1 reference

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Neuromyelitis optica: a positive appraisal of seronegative cases.

21 January 2018

1 reference

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

21 January 2018

1 reference

Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients

21 January 2018

1 reference

Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases

21 January 2018

1 reference

The spectrum of MOG autoantibody-associated demyelinating diseases

21 January 2018

1 reference

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study

21 January 2018

1 reference

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

21 January 2018

1 reference

Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort.

21 January 2018

1 reference

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.

21 January 2018

1 reference

Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis

21 January 2018

1 reference

Potassium channel KIR4.1 as an immune target in multiple sclerosis

21 January 2018

1 reference

Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease.

21 January 2018

1 reference

Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.

21 January 2018

1 reference

Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.

21 January 2018

1 reference

Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.

21 January 2018

1 reference

Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein

21 January 2018

1 reference

Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis

21 January 2018

1 reference

Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.

21 January 2018

1 reference

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

21 January 2018

1 reference

Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis

21 January 2018

1 reference

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis

21 January 2018

1 reference

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

21 January 2018

1 reference

Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude

21 January 2018

1 reference

Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.

21 January 2018

1 reference

Neurofilaments as biomarkers in multiple sclerosis

21 January 2018

1 reference

Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event

21 January 2018

1 reference

Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.

21 January 2018

1 reference

Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort

21 January 2018

1 reference

Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.

21 January 2018

1 reference

Lack of association between antimyelin antibodies and progression to multiple sclerosis.

21 January 2018

1 reference

Antimyelin antibodies with no progression to multiple sclerosis.

21 January 2018

1 reference

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

21 January 2018

1 reference

Epitope spreading as an early pathogenic event in pediatric multiple sclerosis

21 January 2018

1 reference

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

21 January 2018

1 reference

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

21 January 2018

1 reference

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

21 January 2018

1 reference

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis

21 January 2018

1 reference

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study

21 January 2018

1 reference

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica

21 January 2018

1 reference

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis

21 January 2018

1 reference

Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases

21 January 2018

1 reference

Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ENE.12759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26010364%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference